Levels of CCL5 are elevated in the serum of patients with depression (50), suggesting, along with the connection with cognitive impairment and NPSLE, that the decrease of CCL5 in the treatment group may have contributed to the improvement in both behavioral indicators we tested for in this study. Here, CCL5 is linked to depressive symptom measurement.